CAR-T cell therapy: Overview
What it does
The job the technology does for people, in a short paragraph
CAR-T therapy treats some blood cancers by turning a patient's own immune cells into cancer killers [1]. The first was approved in the United States in 2017 for children with acute lymphoblastic leukaemia [1, 3]. By 2025 seven CAR-T therapies were approved there, for leukaemias, lymphomas and multiple myeloma [1].
as of 2026-11-11
How it works
The working principle in plain words, step by step
T cells are white blood cells that kill infected or abnormal cells, but they often miss cancer. Doctors first collect the patient's blood and separate out the T cells [1]. In a manufacturer's laboratory the cells receive a new gene so that they make a chimeric antigen receptor, or CAR, on their surface [1, 3]. The changed cells are grown to hundreds of millions and infused back in one dose [1]. When a CAR locks onto its marker on a cancer cell, such as CD19 on leukaemia cells, the T cell is switched on, kills the cell and multiplies [4].
as of 2026-11-11
Key figures
The handful of numbers that size it up, each with its unit, year and source
| Figure | Value | Unit | Year | Source |
|---|---|---|---|---|
| CAR-T therapies approved by the US Food and Drug Administration | 7 | products | 2025 | [1] |
| Patients with complete remission after one dose in the trial behind Kymriah's approval | 83 | % | 2017 | [4] |
| Launch price of Kymriah, a one-time treatment | 475,000 | USD | 2017 | [5] |
| Time to make one patient's cells (low end of 3 to 5 weeks) | 3 | weeks | 2025 | [1] |
| Large cell lymphoma patients alive with no sign of cancer five years after treatment (more than) | 30 | % | 2025 | [1] |
as of 2026-11-11. The NCI figures carry the page's update date of 26 February 2025; the remission and price figures carry the 2017 publication year of those reports, as neither sentence gives a data year [1, 4, 5].
Where it is used
The main places and products the technology is found in
- B-cell acute lymphoblastic leukaemia in children and young adults
- Large B-cell and other lymphomas
- Multiple myeloma
- Chronic lymphocytic leukaemia
- Specialist cancer centres able to manage its side effects
as of 2026-11-11
Scale today
How much of it there is now: units in use, made each year and who uses it
- Installed
- Seven therapies approved in the United States [1]
- Unit
- approved products
- Year
- 2025
- Note
- No count of patients treated worldwide was found; each dose is made for one patient [1].
as of 2026-11-11
Sources
- CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers National Cancer Institute (NIH), 2025
- FDA Approves Novartis' CAR-T Drug, First Gene Therapy Approval in US Pharmaceutical Technology, 2017
- FDA Approves Personalized Cellular Therapy for Advanced Leukemia (news release) Penn Medicine, 2017
- 'Historic Action': FDA Approves First CAR-T Therapy Regulatory Affairs Professionals Society (RAPS), 2017